Jordan Emerges as Global and Regional Leader in Pharmaceutical Manufacturing

156

Jordan’s pharmaceutical manufacturing sector has gained global and regional recognition, with Muhammad Al Khalayleh, Chairman of the Health and Food Committee, highlighting the country’s leadership in the field. The acknowledgement came during a committee meeting focused on discussing a draft medical supplies examination system. The meeting included the participation of Nizar Muhaidat, Director General of the Jordan Food and Drug Administration (JFDA).

The discussion primarily revolved around the draft of a medical supplies examination system for the year 2023, designed to align with evolving developments and modern requirements in drug testing. The amendment aims to separate the medical supplies examination system from the drug testing system, considering the significant differences between the two.

Al Khalayleh emphasized that the revised system intends to streamline the procedures for local drug registration, fostering increased production. This, in turn, is expected to boost exports and contribute to one of the promising sectors outlined in the Economic Modernisation Vision for the next decade.

Highlighting the significance of the pharmaceutical sector in Jordan’s economy, Al Khalayleh called for efforts to promote the national economy and encourage investments in pharmaceutical manufacturing. He also underscored the importance of exploring alternatives to original drugs to reduce the overall cost of medications.

Nizar Muhaidat shared that Jordan holds the second position globally in pharmaceutical exports. The country boasts 29 pharmaceutical factories producing 481 local drug varieties that are marketed in 72 international markets. The draft system outlined during the meeting prohibits the trading of any registered drug until it undergoes the initial examination. Trading approval is subject to the decision of the JFDA Director General, as per the provisions of the proposed system.